Wednesday February 7, 10:29 am Eastern Time
Press Release
Zola Horovitz, Former Bristol-Myers Squibb Vice
President, Joins Palatin Board
PRINCETON, N.J.--(BUSINESS WIRE)--Feb. 7, 2001--Palatin Technologies today announced the appointment of Zola
Horovitz, Ph.D., to the company's board of directors.
Dr. Horovitz is the retired vice president of business development and planning for Bristol-Myers Squibb Pharmaceutical
Group, and is currently a business consultant to the biotechnology and pharmaceutical industries.
``We are delighted to welcome Dr. Horovitz to the Palatin board,'' said John Prendergast, Ph.D., and Chairman of Palatin.
``His considerable expertise in drug development and large pharmaceutical company perspective will serve Palatin well as we
advance our products through clinical trials and toward commercialization.''
Dr. Horovitz began his long career in the pharmaceutical industry in 1959 as a research pharmacologist with the Squibb
Institute of Medical Research. During subsequent years, he held a number of increasingly important positions with Squibb in the
area of product development, including director of the department of pharmacology; associate director of research and
development; vice president, drug development; and vice president, research, planning, and scientific liaison. With the merger of
Squibb and Bristol-Myers in 1990, Dr. Horovitz was appointed vice president, licensing, and held the position of vice
president, business development and planning at his retirement in 1994.
Dr. Horovitz has also held a number of academic positions, including visiting professor of psychiatry at the Rutgers University
School of Medicine, and visiting professor of pharmacology at the Rutgers University School of Pharmacy. He has also been a
member of the scientific advisory council at Princeton University, the advisory board at Rutgers University College of
Pharmacy, and the visitors board, University of Pittsburgh School of Pharmacy. Dr. Horovitz was previously awarded the A.E.
Bennett Neuropsychiatric Research Award and was also a winner of the American Heart Association Discovery Award for
work on the development of angiotensin converting enzyme inhibitors. Dr. Horovitz holds a Ph.D. in pharmacology from the
University of Pittsburgh. He is the author of several patents, and over 60 books, articles, and abstracts.
Palatin Technologies, Inc. is a development-stage medical technology company developing and commercializing pharmaceutical
products for diagnostic imaging and therapy based on its proprietary monoclonal antibody radiolabeling and enabling peptide
platform technologies. For further information visit the Palatin web site at www.palatin.com.
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in
this document other than historical facts, are ``forward-looking statements'' within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Action of 1934 and as that term is defined in the Private Securities
Litigation Reform Action of 1995. The Company intends that such forward-looking statements be subject to the safe harbors
created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's
actual results could differ materially from expected results.
Contact:
Palatin Technologies, Inc.
Carl Spana, Ph.D., 609/520-1911
cspana@palatin.com
or
Stephen T. Wills, 609/520-1911
swills@palatin.com
or
Kureczka/Martin Associates (Media Relations)
Joan Kureczka/Jesse Fisher, 415/821-2413
Jkureczka@aol.com |
